Seagen (United States)
In research, Seagen (United States) stands highest in Medicine (#3,434 of 17,978 worldwide), Health Sciences (#4,554 of 20,462 worldwide) and Life Sciences (#4,546 of 14,347 worldwide), over all time. Relative to its size it is most specialised in Oncology — Oncology is 21.1× its share of world research.
- World rank, 2022–2025
- #16,785 of 28,054 · #8,008 all time
- Rank in United States
- #2,389 of 4,192
- Research works
- 613 ▲ 26% vs 2013–17
- Citations
- 56k 90.7 per fractional work
- Top-10% rate
- 15.7% record average 16.5%
- Open access
- 30% world 28%
What is Seagen (United States) known for in research?
The fields where it stands highest, over all time, ranked among every institution above the floor in each field.
| Field | World rank | Where that sits | Top-10% rate | Works |
|---|---|---|---|---|
| MedicineField | #3,434 of 17,978 | 26.7% | 371 | |
| Health SciencesDomain | #4,554 of 20,462 | 26.8% | 380 | |
| Life SciencesDomain | #4,546 of 14,347 | 27.2% | 181 | |
| OncologySubfield | #684 of 1,852 | 27.7% | 129 | |
| Biochemistry, Genetics and Molecular BiologyField | #5,582 of 7,814 | 26.1% | 130 |
Each strip is that field’s whole ranked pool, with the notch where Seagen (United States) sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no world mark, because the world rate differs by field (from about 6% to 21% in this record).
What does Seagen (United States) specialise in?
Where its research is concentrated relative to its size: Oncology takes 21.1× the share of its output that it takes of world research.
- OncologySubfield · 20.4 works21×
Location quotient, a volume reading rather than an impact one. It surfaces small, lopsided specialities.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 6.1×. Every wedge is a field page.
- Immunology and Microbiology 6.1×
- Medicine 3.5×
- Veterinary 3.0×
- Biochemistry, Genetics and Molecular Biology 2.1×
- Pharmacology, Toxicology and Pharmaceutics 1.9×
- Economics, Econometrics and Finance 1.4×
- Chemistry 1.1×
- Mathematics 0.9×
- Nursing 0.7×
- Neuroscience 0.3×
- Decision Sciences 0.2×
- Computer Science 0.2×
- Materials Science 0.2×
- Engineering 0.2×
- Health Professions 0.2×
- Dentistry 0.1×
- Environmental Science 0.1×
- Psychology 0.1×
- Agricultural and Biological Sciences 0.1×
- Social Sciences 0.0×
Who are the top researchers at Seagen (United States)?
Ranked on the composite score, Iqbal S. Grewal, Scott Peterson and Peter D. Senter lead among researchers whose main affiliation is Seagen (United States).
- 1 Iqbal S. Grewal United States · #178,278 worldwide 135 citations · 23 works
- 2 Scott Peterson United States · #324,137 worldwide 144 citations · 27 works
- 3 Peter D. Senter United States · #332,287 worldwide 158 citations · 24 works
- 4 Michelle Ulrich United States · #659,280 worldwide 45 citations · 19 works
- 5 Jorge Ramos United States · #781,185 worldwide 25 citations · 16 works
- 6 Fu Li United States · #987,753 worldwide 27 citations · 19 works
- 7 Anthony Lee United States · #1,059,045 worldwide 36 citations · 18 works
- 8 Che‐Leung Law United States · #1,191,678 worldwide 51 citations · 31 works
- 9 Patrick Burke United States · #1,334,716 worldwide 9 citations · 26 works
- 10 Katherine Holmes United States · #1,354,085 worldwide 2 citations · 926 works
Which keywords describe research at Seagen (United States)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Chemotherapy, Breast Cancer, Immunotherapy, Trastuzumab, Monoclonal Antibody, Metastatic, Lymphoma and EGFR.
- PD-1 and PD-L1
- Metastatic Breast Cancer
- Bladder Cancer
- Chimeric Antigen Receptor
- Leukemia
- ALK Inhibitors
- Treatment Guidelines
- Tumor Regression
- Classification
- Cancer Immunotherapy
- Gene Expression Profiling
- Molecular Characterization
- Antibody Engineering
- Rituximab
- Targeted Therapy
- Monoclonal Antibodies
- EGFR
- Lymphoma
- Monoclonal Antibody
- Breast Cancer
- Chemotherapy
- Immunotherapy
- Trastuzumab
- Metastatic
- HER2
- Glycosylation
- PET Imaging
- Therapeutic Antibodies
- Fc Receptors
- Clinical Trials
- Molecular Profiling
- Neoadjuvant Therapy
- Genetic Pathogenesis
- Genomic Profiling
- Tumor Microenvironment
- EGFR Mutations
- CAR T Cells
- Prognostic Factors
- Urothelial Carcinoma
- Immune Checkpoint Blockade
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Chemotherapy17▲ 29×15 topics
- Breast Cancer10▲ 50×3 topics
- Immunotherapy10▲ 16×13 topics
- Monoclonal Antibody8▲ 181×2 topics
- Trastuzumab8▲ 210×2 topics
- Lymphoma8▲ 58×3 topics
- Metastatic8▲ 151×2 topics
- EGFR8▲ 321×1 topic
- HER28▲ 321×1 topic
- Monoclonal Antibodies6▲ 84×3 topics
- Glycosylation6▲ 61×3 topics
- Targeted Therapy6▲ 30×5 topics
- PET Imaging6▲ 38×5 topics
- Rituximab5▲ 42×2 topics
- Therapeutic Antibodies5▲ 90×2 topics
- Antibody Engineering5▲ 108×1 topic
- Fc Receptors5▲ 108×1 topic
- Molecular Characterization5▲ 32×4 topics
- Clinical Trials5▲ 8.2×7 topics
- Gene Expression Profiling5▲ 68×2 topics
- Molecular Profiling5▲ 56×2 topics
- Cancer Immunotherapy5▲ 35×3 topics
- Neoadjuvant Therapy4▲ 22×4 topics
- Classification4▲ 11×1 topic
- Genetic Pathogenesis4▲ 95×1 topic
- Tumor Regression4▲ 44×2 topics
- Genomic Profiling4▲ 46×2 topics
- Treatment Guidelines4▲ 21×2 topics
- Tumor Microenvironment4▲ 10×4 topics
- ALK Inhibitors4▲ 74×1 topic
- EGFR Mutations4▲ 74×1 topic
- Leukemia4▲ 51×2 topics
- CAR T Cells4▲ 55×1 topic
- Chimeric Antigen Receptor4▲ 55×1 topic
- Prognostic Factors4▲ 9.2×10 topics
- Bladder Cancer3▲ 105×1 topic
- Urothelial Carcinoma3▲ 91×1 topic
- Metastatic Breast Cancer3▲ 69×2 topics
- Immune Checkpoint Blockade3▲ 34×1 topic
- PD-1 and PD-L13▲ 34×1 topic
Which research topics does Seagen (United States) publish most on?
By volume in 2022–2025: HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research, Lymphoma Diagnosis and Treatment and Lung Cancer Treatments and Mutations.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 HER2/EGFR in Cancer Research Oncology 8 works
- 2 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 5 works
- 3 Lymphoma Diagnosis and Treatment Pathology and Forensic Medicine 4 works
- 4 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 4 works
- 5 CAR-T cell therapy research Oncology 4 works
- 6 Bladder and Urothelial Cancer Treatments Surgery 3 works
- 7 Cancer Immunotherapy and Biomarkers Oncology 3 works
- 8 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 2 works
- 9 Economic and Financial Impacts of Cancer Economics and Econometrics 2 works
- 10 Colorectal Cancer Treatments and Studies Oncology 2 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Seagen (United States)'s research output changed?
Output in 2018–2022 was 26% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Bothell
- University of Washington Bothell
- Modern Electron (United States)
- Radar (United States)
- EKOS Corporation
- Epoch Biosciences (United States)
- OncoGenex Pharmaceuticals (United States)
- Sonic Concepts (United States)
- Ondine Biopharma (United States)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.